AtriCure, Inc. (NASDAQ:ATRC) Stock Has Average Price Target of $54.10

Key Points

• Analysts maintain a moderately bullish view: AtriCure has a consensus “Moderate Buy” rating from 12 analysts, with seven buys and five holds. The average 12-month price target is $54.10.
• Shares are trading near their annual high: ATRC opened at $57.67 and recently gained 3.9%, compared with a 52-week range of $25.36 to $61.70. The stock has a $2.93 billion market capitalization and a high P/E ratio of 274.63.
• Quarterly results exceeded expectations, but insiders have been selling: AtriCure reported $0.18 in quarterly EPS and $153.6 million in revenue, topping the $151.8 million estimate. Insiders sold 74,868 shares worth approximately $3.32 million over the past 90 days, while institutional investors own 99.11% of the company.

Shares of AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve research firms that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $54.10.

A number of research firms have commented on ATRC. Piper Sandler raised their price target on shares of AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, August 27th. BTIG Research upped their price target on AtriCure from $55.00 to $63.00 and gave the stock a "buy" rating in a report on Monday, October 12th. UBS Group dropped their target price on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, July 28th. Needham & Company LLC boosted their price target on shares of AtriCure from $45.00 to $64.00 and gave the stock a "buy" rating in a report on Wednesday, September 2nd. Finally, Weiss Ratings upgraded shares of AtriCure from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th.

AtriCure Trading Up 3.9%

NASDAQ:ATRC opened at $57.67 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The firm has a market cap of $2.93 billion, a P/E ratio of 274.63 and a beta of 1.24. The firm's fifty day moving average is $53.28 and its 200-day moving average is $38.68. AtriCure has a 52 week low of $25.36 and a 52 week high of $61.70.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%. The firm had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same period last year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities analysts expect that AtriCure will post 0.29 earnings per share for the current year.

Insider Activity at AtriCure

In related news, Director Karen Prange sold 3,564 shares of AtriCure stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the sale, the director owned 22,809 shares of the company's stock, valued at approximately $884,989.20. The trade was a 13.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Karl Dahlquist sold 9,370 shares of the company's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the transaction, the insider owned 87,319 shares in the company, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 74,868 shares of company stock worth $3,317,897 over the last 90 days. Corporate insiders own 4.00% of the company's stock.

Hedge Funds Weigh In On AtriCure

Several large investors have recently modified their holdings of ATRC. Harbor Investment Advisory LLC purchased a new stake in shares of AtriCure in the second quarter worth about $40,000. Allworth Financial LP purchased a new position in AtriCure in the second quarter worth $43,000. Integrated Wealth Concepts LLC purchased a new position in shares of AtriCure in the 2nd quarter worth about $46,000. Fifth Third Bancorp bought a new position in AtriCure during the first quarter valued at approximately $51,000. Finally, Global Retirement Partners LLC bought a new position in shares of AtriCure during the 2nd quarter valued at $52,000. Hedge funds and other institutional investors own 99.11% of the company's stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company's product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.